Focused On-demand Library for Asparagine--tRNA ligase, cytoplasmic

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O43776

UPID:

SYNC_HUMAN

Alternative names:

Asparaginyl-tRNA synthetase; Asparaginyl-tRNA synthetase 1

Alternative UPACC:

O43776; B4DG16; Q53GU6

Background:

Asparagine--tRNA ligase, cytoplasmic, also known as Asparaginyl-tRNA synthetase, plays a pivotal role in protein synthesis by catalyzing the attachment of asparagine to tRNA(Asn). This enzyme not only facilitates the accurate translation of the genetic code into functional proteins but also acts as a signaling molecule, influencing cell migration. Its essential contribution to the development of the cerebral cortex, through the proliferation of radial glial cells, underscores its significance in neurodevelopment.

Therapeutic significance:

The protein's involvement in neurodevelopmental disorders with microcephaly, impaired language, and gait abnormalities highlights its therapeutic potential. Understanding the role of Asparagine--tRNA ligase, cytoplasmic could open doors to potential therapeutic strategies for these conditions, offering hope for interventions that could mitigate or reverse the developmental delays and neurological symptoms associated with these diseases.